Evidence map›Paper›PMID 40723266›Full record

ArticleCancers2025

Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study.

Makoto Watanabe, Katsuaki Ieguchi, Takashi Shimizu, Ryotaro Ohkuma, Risako Suzuki, Emiko Mura, Nana Iriguchi, Tomoyuki Ishiguro, Yuya Hirasawa, Go Ikeda and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Makoto WatanabeDepartment of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.
Katsuaki IeguchiDepartment of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.ORCID 0000-0002-8509-846X
Takashi ShimizuDepartment of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.
Ryotaro OhkumaDivision of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.
Risako SuzukiDepartment of Pharmacology, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.
Emiko MuraDivision of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.
Nana IriguchiDivision of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.
Tomoyuki IshiguroDivision of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.
Yuya HirasawaDivision of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.
Go IkedaDivision of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.
Masahiro ShimokawaDivision of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.
Hirotsugu AriizumiDivision of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.
Kiyoshi YoshimuraClinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.
Atsushi HoriikeDivision of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.
Takuya TsunodaDivision of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.ORCID 0000-0002-6416-8211
Mayumi TsujiPharmacological Research Center, Showa Medical University, Tokyo 142-8555, Japan.ORCID 0000-0001-8005-9069
Shinichi KobayashiClinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.
Tatsunori OguchiDepartment of Pharmacology, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.
Yuji KiuchiDepartment of Pharmacology, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.
Satoshi WadaDepartment of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.ORCID 0000-0001-6528-5914

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

biomarkerimmune checkpoint inhibitorstumor progressionWFDC2

Identifiers

PMID40723266
PMCPMC12293223

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.